Lumos Pharma, Inc.
Extract: Charter Amendment (Plain English Desc) from a 8-K on 03/18/2020   Download
SEC Document
SEC Filing
On March 17, 2020, at a special meeting of the Company’s stockholders (the “Special Meeting”), the stockholders approved an amendment to the Company’s amended and restated certificate of incorporation, as amended (the “Restated Certificate”) to effect the Reverse Stock Split (the “Split Amendment”).  Additionally, the Board previously approved on September 30, 2019 an amendment to the Restated Certificate to change the Company’s name from “NewLink Genetics Corporation” to “Lumos Pharma, Inc.” (the “Name Change Amendment”) upon closing of the Merger.  On March 18, 2020, the Company filed the Split Amendment, effective prior to the Effective Time, and the Name Change Amendment, effective immediately after the Effective Time, with the Secretary of State of the State of Delaware.